No Data
No Data
No Data
No Data
No Data
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis In Neurology Neuroimmunology & Neuroinflammation
30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks.Improvements in Serum Neurofilament Lig
BenzingaApr 30 18:32
Immunic CEO Dr Daniel Vitt Marks International Day of Immunology With Discussion on Its Crucial Role
Yahoo FinanceApr 29 23:11
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
TipRanksApr 16 14:50
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Seeking AlphaApr 12 23:34
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
TipRanksApr 10 19:20
Brookline Capital Starts Immunic at Buy, Cites MS Drug Candidate
Seeking AlphaApr 6 01:00
No Data
No Data